Journal of Endocrinological Investigation

, Volume 24, Issue 5, pp 340–348 | Cite as

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome

  • Graziano Grugni
  • G. Guzzaloni
  • F. Morabito
Original Article


The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7–38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9–42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2–14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 μg/kg, iv) or GHRH (1 μg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4±2.0; AUC: 588±113; nAUC: 483±108) and GHRH+PD (GHp: 7.3±1.8; AUC: 486±122; nAUC: 371±250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7±3.2, p<0.003; AUC: 1833±305, p<0.005; nAUC: 1640±263, p<0.0001. GHRH+PD: GHp: 15.1±2.4, p<0.009; AUC: 1249±248, p<0.003; nAUC: 918±230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1±3.1, p<0.0001; AUC: 2792±158, p<0.0001; nAUC: 2705±165, p<0.00005. GHRH+PD: GHp: 27.5±3.7, p<0.0001; AUC: 1873±251, p<0.0001; nAUC: 1692±219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.


Prader-Willi syndrome short stature obesity GH GHRP-6 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bowers C.Y., Sartor A.O., Reynolds G.A., Badger T.M. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027–2035.PubMedCrossRefGoogle Scholar
  2. 2.
    Howard A., Feighner S., Cully D., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., McKee K.K., Pong S.S., Chaung L.Y.P., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R.P., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., Van der Ploeg L.H.T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–977.PubMedCrossRefGoogle Scholar
  3. 3.
    Guillaume V., Magnan E., Cataldi M., Dutour A., Sauze N., Renard M., Razafindraibe H., Conte-Devolx B., Deghenghi R., Lenaerts V., Oliver C. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994, 135: 1073–1076.PubMedGoogle Scholar
  4. 4.
    Bowers C.Y. Editorial: On a peptidomimetic growth hormone-releasing peptide. J. Clin. Endocrinol. Metab. 1994, 79: 940–942.PubMedGoogle Scholar
  5. 5.
    Korbonits M., Grossman A.B. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol. Metab. 1995, 6: 43–49.PubMedCrossRefGoogle Scholar
  6. 6.
    Micic D., Popovic V., Kendereski A., Macut D., Casanueva F.F., Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin. Endocrinol. (Oxf.) 1995, 42: 191–194.CrossRefGoogle Scholar
  7. 7.
    Penalva A., Carballo A., Pombo M., Casanueva F.F., Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6 induced GH secretion in man. J. Clin. Endocrinol. Metab. 1993, 76: 168–171.PubMedGoogle Scholar
  8. 8.
    Penalva A., Pombo M., Carballo A., Barreiro J., Casanueva F.F., Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin. Endocrinol. (Oxf.) 1993, 38: 87–91.CrossRefGoogle Scholar
  9. 9.
    Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. 1995, 80: 942–947.PubMedGoogle Scholar
  10. 10.
    Popovic V., Damjanovic S., Micic D., Petakov M., Dieguez C., Casanueva F.F. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone, and GH-releasing peptide-6. J. Clin. Endocrinol. Metab. 1994, 79: 456–460.PubMedGoogle Scholar
  11. 11.
    Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.PubMedCrossRefGoogle Scholar
  12. 12.
    Pombo M., Leal Cerro A., Barreiro J., Penalva A., Peino R., Mallo F., Dieguez C., Casanueva F.F. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J. Pediatr. Endocrinol. Metab. 1996, 9 (Suppl. 3): 333–338.PubMedGoogle Scholar
  13. 13.
    Scacchi M., Pincelli A.I., Cavagnini F. Growth hormone in obesity. Int. J. Obes. Relat. Metab. Disord. 1999, 23: 260–271.PubMedCrossRefGoogle Scholar
  14. 14.
    Argente J., Caballo N., Barrios V., Munoz M.T., Pozo J., Chowen J.A., Hernandez M. Disturbances in the growth hormone-insulin-like growth factor axis in children and adolescents with different eating disorders. Horm. Res. 1997, 48 (Suppl. 4): 16–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Cordido F., Penalva A., Peino R., Casanueva F.F., Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995, 44: 745–748.PubMedCrossRefGoogle Scholar
  16. 16.
    Burd L., Veselly B., Martsolf J., Kerbeshian J. Prevalence study of Prader-Willi syndrome. Lancet 1985, 2: 828–829.Google Scholar
  17. 17.
    Donaldson M.D.C., Chu C.E., Cooke A., Wilson A., Greene S.A., Stephenson J.B.P. The Prader-Willi syndrome. Arch. Dis. Child. 1994, 70: 58–63.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Grugni G., Guzzaloni G., Moro D., Bettio D., De Medici C., Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 1998, 48: 769–775.CrossRefGoogle Scholar
  19. 19.
    Cappa M., Grossi A., Borrelli P., Ghigo E., Bellone J., Benedetti S., Carta D., Loche S. Growth Hormone (GH) response to combined pyridostigmine and GH-Releasing Hormone administration in patients with Prader-Labhardt-Willi syndrome. Horm. Res. 1993, 39: 51–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., Greenberg F. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993, 91: 398–402.PubMedGoogle Scholar
  21. 21.
    Rolland-Cachera M.F., Sempè M., Guilloud-Bataille M., Patois E., Pequinot-Gugenbuhl F., Fautrad V. Adiposity indices in children. Am. J. Clin. Nutr. 1982, 36: 178–184.PubMedGoogle Scholar
  22. 22.
    Joint FAO/WHO/UNU: Expert consultation. Energy and protein requirements. WHO Technical Report Series, no. 724, WHO, Geneva, 1985.Google Scholar
  23. 23.
    Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch. Dis. Child. 1966, 41: 613–635.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in girls. Arch. Dis. Child. 1969, 44: 291–303.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in boys. Arch. Dis. Child. 1970, 45: 13–23.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Spiliotis B.E., August G.P., Hung W., Mendelson W., Bercu B.B. Growth hormone neurosecretory dysfunction: a treatable cause of short stature. JAMA 1984, 251: 2223–2230.PubMedCrossRefGoogle Scholar
  27. 27.
    Dammacco F., Boghen M.F., Camanni F., Cappa M., Ferrari C., Ghigo E., Giordano G., Loche S., Minuto F., Mucci M., Muller E.E., the Italian Collaborative Group of Neuroendocrinology. Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. J. Clin. Endocrinol. Metab. 1993, 77: 68–72.PubMedGoogle Scholar
  28. 28.
    Loche S., Pintus S., Cella S.G., Boghen M., Vannelli V., Benso L., Muller E.E., Corda R., Pintor C. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children. Clin. Endocrinol. (Oxf.) 1990, 33: 187–192.CrossRefGoogle Scholar
  29. 29.
    Angulo M., Castro-Magana M., Mazur B., Canas J.A., Vitollo P.M., Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1996, 9: 393–400.PubMedCrossRefGoogle Scholar
  30. 30.
    Vanderschueren-Lodeweyckx M. The effect of simple obesity on growth and growth hormone. Horm. Res. 1993, 40: 23–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Wollmann H.A., Schultz U., Grauer M.L., Ranke M.B. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur. J. Pediatr. 1998, 157: 634–642.PubMedCrossRefGoogle Scholar
  32. 32.
    Thacker M.J., Hainline B., St. Dennis-Feezle L., Johnson N.B., Pescovitz O.H. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm. Res. 1998, 49: 216–220.PubMedCrossRefGoogle Scholar
  33. 33.
    Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr. Scand. 1990, 79: 1059–1062.PubMedCrossRefGoogle Scholar
  34. 34.
    Arvat E., Camanni F., Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr. 1997, 423 (Suppl.): 92–96.CrossRefGoogle Scholar
  35. 35.
    Loche S., Cambiaso P., Carta D., Setzu S., Imbimbo B.P., Borrelli P., Pintor C., Cappa M. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J. Clin. Endocrinol. Metab. 1995, 80: 674–678.PubMedGoogle Scholar
  36. 36.
    Loche S., Cambiaso P., Merola B., Colao A., Faedda A., Imbimbo B.P., Deghenghi R., Lombardi G., Cappa M. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J. Clin. Endocrinol. Metab. 1995, 80: 2692–2696.PubMedGoogle Scholar
  37. 37.
    Pombo M., Barreiro J., Penalva A., Peino R., Dieguez C., Casanueva F.F. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J. Clin. Endocrinol. Metab. 1995, 80: 3180–3184.PubMedGoogle Scholar
  38. 38.
    Sieg K.G., Gaffney G.R., Preston D.F., Erikson H.M. SPECT brain imaging of Prader-Willi syndrome using technetium-99m-hexamethylpropyleneamine oxime. Am. J. Med. Genet. 1991, 41: 529.Google Scholar
  39. 39.
    Butler M.G., Kessler R.M. Positron emission tomography of three adult patients with Prader-Willi syndrome. Dysmorph. Clin. Genet. 1992, 6: 30–31.Google Scholar
  40. 40.
    Miller L., Angulo M., Price D., Taneja S. MR of the pituitary in patients with Prader-Willi syndrome: size determination and imaging findings. Pediatr. Radiol. 1996, 26: 43–47.PubMedCrossRefGoogle Scholar
  41. 41.
    Corrias A., Bellone J., Beccaria L., Bosio L., Trifirò G., Livieri C., Ragusa L., Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crinò A. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of somatotroph responsiveness to various provocative stimuli. J. Endocrinol. Invest. 2000, 23: 84–89.PubMedCrossRefGoogle Scholar
  42. 42.
    Hochberg Z., Hertz P., Colin V., Ish-Shalom S., Yeshurun D., Youdim M.B.H., Amit T. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-1 (IGF-I), and IGF-1 receptors in obesity and anorexia nervosa. Metabolism 1992, 41: 106–112.PubMedCrossRefGoogle Scholar
  43. 43.
    Robinson I.C.A.F. Hypothalamic targets for growth hormone secretagogues. Acta Paediatr. 1997, 423 (Suppl.): 88–91.CrossRefGoogle Scholar
  44. 44.
    Casanueva F.F., Micic D., Pombo M., Leal A., Bokser L., Zugaza J.L., Dieguez C. Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies. Metabolism 1996, 8 (Suppl. 1): 123–126.CrossRefGoogle Scholar
  45. 45.
    Swaab D.F. Prader-Willi syndrome and the hypothalamus. Acta Paediatr. 1997, 423 (Suppl.): 50–54.CrossRefGoogle Scholar
  46. 46.
    Loche S., Balzano S., Bozzola M., Moretta A., Pintus S., Faedda A., Muntoni A., Carta D., Pintor C. Secretion of growth hormone releasing hormone in obese children. J. Endocrinol. Invest. 1992, 15: 453–457.PubMedCrossRefGoogle Scholar
  47. 47.
    Procopio M., Ghigo E., Maccario M., Boffano G.M., Oleandri S.E., Arvat E., Bellone J., Mucci M., Boghen M.F., Camanni F. Effects of arginine, repeated growth hormone (GH)-releasing hormone (GHRH) administration and fasting on the acute GH response to GHRH in obesity. Proceedings International Congress on Growth Hormone and Somatomedins during Lifespan, Milan, Italy, 1992. J. Endocrinol. Invest. 1992, 15 (Suppl. 4): 47 (Abstract).Google Scholar
  48. 48.
    Low L.C.K., Wang C., Cheung P.T., Ho P., Lam K.S.L., Young R.T.T., Yeung C.Y., Ling N. Long-term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. J. Clin. Endocrinol. Metab. 1988, 66: 611–617.PubMedCrossRefGoogle Scholar
  49. 49.
    Goth M.I., Lyons C.E., Canny B.J., Thorner M.O. Pituitary adenylate cyclase activating polypeptide growth hormone(GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992, 130: 939–944.PubMedGoogle Scholar
  50. 50.
    Mericq V., Cassorla F., Garcia H., Avila A., Bowers C.I., Merriam G.R. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J. Clin. Endocrinol. Metab. 1995, 80: 1681–1684.PubMedGoogle Scholar
  51. 51.
    Clark R.G., Carlsson L.M.S., Trojnar J., Robinson I.C.A.F. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J. Neuroendocrinol. 1989, 1: 249–255.PubMedCrossRefGoogle Scholar
  52. 52.
    Ritzen E.M., Lindgren A.C., Hagenas L., Marcus C., Muller J., Blichfeldt S. Growth hormone treatment of patients with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1999, 12: 345–349.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2001

Authors and Affiliations

  1. 1.Division of AuxologyIRCCS S. Giuseppe Hospital, Istituto Auxologico Italiano FoundationVerbania IntraItaly

Personalised recommendations